A
Anusha Ponduri
Researcher at National Institutes of Health
Publications - 4
Citations - 414
Anusha Ponduri is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Chimeric antigen receptor & Cancer. The author has an hindex of 3, co-authored 3 publications receiving 207 citations.
Papers
More filters
Journal ArticleDOI
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah,Steven L. Highfill,Haneen Shalabi,Bonnie Yates,Jianjian Jin,Pamela L. Wolters,Amanda K. Ombrello,Seth M. Steinberg,Staci Martin,Cindy Delbrook,Leah Hoffman,Lauren Little,Anusha Ponduri,Haiying Qin,Haris Qureshi,Alina Dulau-Florea,Dalia Salem,Hao-Wei Wang,Constance M. Yuan,Maryalice Stetler-Stevenson,Sandhya R. Panch,Minh Tran,Crystal L. Mackall,Crystal L. Mackall,David F. Stroncek,Terry J. Fry,Terry J. Fry +26 more
TL;DR: The remission induction rate supports further development of CD22 CAR T cells as a therapeutic option in patients resistant to CD19-targeted immunotherapy, and novel information on the impact of manufacturing changes on clinical outcomes is provided.
Journal ArticleDOI
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.
Haiying Qin,Sneha Ramakrishna,Sang M. Nguyen,Thomas J. Fountaine,Anusha Ponduri,Maryalice Stetler-Stevenson,Constance M. Yuan,Waleed Haso,Jack F. Shern,Nirali N. Shah,Terry J. Fry +10 more
TL;DR: It is hypothesized that simultaneous targeting of CD19 and CD22 may reduce the likelihood of antigen loss, thus improving sustained remission rates, and a systematic approach to the generation of CAR constructs incorporating two target-binding domains led to several novel CD19/CD22 bivalent CAR constructs.
Journal ArticleDOI
Case report: Impact of BITE on CAR‐T cell expansion
Haneen Shalabi,Ashley K. Koegel,Anusha Ponduri,Haiying Qin,Dalia Salem,Dalia Salem,Maryalice Stetler-Stevenson,Constance M. Yuan,Bonnie Yates,Cindy Delbrook,Mignon L. Loh,Terry J. Fry,Terry J. Fry,Nirali N. Shah +13 more
TL;DR: A case of relapsed, refractory B‐ALL that has immunophenotypic variability in the leukemia blasts in response to the sequential targeted immunotherapies received is presented, suggesting a potential strategy for utilization of multiagent immunotherAPies to have synergistic approaches to eradicate disease and prolong remission in patients with relapsed hematologic malignancies.
Journal ArticleDOI
The Efficacy of Human Papillomavirus Vaccination as an Adjuvant Therapy in Recurrent Respiratory Papillomatosis.
Anusha Ponduri,Monica C. Azmy,Eden Axler,Juan Lin,R. Schwartz,Magdalena Chirila,Frederik G. Dikkers,Christina J. Yang,Vikas Mehta,Mona Gangar +9 more
TL;DR: In this paper , a random-effects meta-analysis was performed to study intersurgical interval (ISI) and number of surgical procedures per year before and after vaccination, with a mean difference of 15.73 months (95% CI, 1.46-29.99).